

## CURRICULUM VITAE

**DATE:** October 2023

**NAME:** Hillary Samples, PhD, MHS

**PRESENT TITLE:** Assistant Professor of Health Systems and Policy, Department of Health Behavior, Society and Policy, Rutgers School of Public Health  
Core Faculty, Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research

**E-MAIL ADDRESS:** [h.samples@rutgers.edu](mailto:h.samples@rutgers.edu)

### **EDUCATION:**

Johns Hopkins Bloomberg School of Public Health  
*Baltimore, MD*  
Doctor of Philosophy (Health Services Research and Policy) Aug 2017  
Certificate of Bioethics and Public Health Policy May 2015  
Master of Health Science (Mental Health) May 2013

University of Virginia  
*Charlottesville, VA*  
Bachelor of Arts (Psychology and Spanish) May 2007

### **POSTGRADUATE TRAINING:**

Columbia University Mailman School of Public Health  
*New York, NY*  
Post-doctoral Research Fellow 2017 – 2020  
Substance Use Epidemiology Training Program (T32 DA031099; PI: Hasin)

### **ACADEMIC APPOINTMENTS:**

Rutgers School of Public Health  
*Department of Health Behavior, Society and Policy*  
Assistant Professor of Health Systems and Policy 2020 – present

Rutgers Institute for Health, Health Care Policy and Aging Research  
*Center for Pharmacoepidemiology and Treatment Science (PETS)*  
Core Faculty 2022 – present  
*Center for Health Services Research*  
Associate Director for Research 2020 – 2022

### **MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:**

Rutgers Institute for Nicotine and Tobacco Studies (INTS), Associate Member 2022 – present  
Rutgers Addiction Research Center (RARC), Affiliate 2022 – present  
Medicaid Data Learning Network, Site Lead 2022 – present  
New Jersey Alliance for Clinical and Translational Sciences (NJ ACTS), Member 2020 – present  
Addiction Health Service Research Conference Planning Committee 2020 – present

- Pre-conference Workshops Subcommittee (2022 – 2023)
- Investigator Awards Subcommittee (2020 – 2021)

College on Problems of Drug Dependence, Member	2018 – present
□ Member in Training (2018 – 2022)	
American Psychopathological Association, Member	2018 – present
□ Trainee Member (2018 – 2020)	
Society for Epidemiologic Research, Member	2017 – present
□ Conference Abstract Reviewer (2022)	
American Statistical Association, Member	2015 – present
□ Student Member (2015-2017)	
Academy Health, Member	2014 – present
□ Student Member (2014-2018)	
American Society of Addiction Medicine, Member	2019
New York Academy of Sciences, Member	2017 – 2018

#### HONORS AND AWARDS:

Society of Scholars, New Jersey Alliance for Clinical and Translational Science	2022 – present
Early Career Investigator Award, Addiction Health Services Research Conference	2020
Delta Omega Honorary Society, Member	2018 – present
Marilyn Bergner Award in Health Services Research	2016 – 2017
June Culley Doctoral Scholarship in Health Policy and Management	2015 – 2016

#### SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

NIH/NIDA Special Emphasis Panel (ZDA1 MXS-E (A1) R), Reviewer	2023
NIH/NIDA Center for the Clinical Trials Network (CTN), Protocol Reviewer	2023

#### SERVICE ON MAJOR COMMITTEES:

<u>University</u>	
Doctoral and Postdoctoral Training Award (TL1) Review Committee <i>New Jersey Alliance for Clinical and Translational Science (NJ ACTS)</i>	2023 – present
<u>Department</u>	
Doctoral Admissions Committee, Member <i>Department of Health Behavior, Society and Policy, Rutgers School of Public Health</i>	2023 – 2024
PhD Qualifying Exam Committee, Member <i>Department of Health Behavior, Society and Policy, Rutgers School of Public Health</i>	2022 – 2023
Population Mental Health Curriculum Development Committee, Member <i>Department of Health Behavior, Society and Policy, Rutgers School of Public Health</i>	2020 – 2021
<u>AdHoc Reviewer</u>	
<i>JAMA</i>	2023 – present
<i>International Journal of Mental Health and Addiction</i>	2022 – present
<i>Journal of Psychiatric Research</i>	2022 – present
<i>JAMA Network Open</i>	2021 – present
<i>Health Affairs</i>	2021 – present
<i>Addiction</i>	2020 – present
<i>Journal of General Internal Medicine</i>	2020 – present
<i>Annals of Internal Medicine</i>	2020 – present
<i>Journal of Addiction Medicine</i>	2019 – present
<i>Substance Abuse Treatment, Prevention, and Policy</i>	2019 – present
<i>Medical Care</i>	2018 – present
<i>Drug and Alcohol Dependence</i>	2018 – present

#### SERVICE TO THE COMMUNITY:

Peer group Research On Mentoring Scientists (PROMISE) Study, Reviewer <i>NIH Diversity Program Consortium, Duke University</i>	2022
---	------

State Policies to Improve Engagement and Retention in Treatment for OUD, Expert Panelist <i>RAND-USC Shaeffer Opioid Policy Tools and Information Center (OPTIC)</i>	2022
Lloyd C. Gardner Fellowship Program, Mentor <i>Rutgers University</i>	2021 – 2022
Annual Recruitment Event, Concentration Representative <i>Department of Health Behavior, Society and Policy, Rutgers School of Public Health</i>	2021 – 2022
Interprofessional Education, Facilitator <i>Rutgers Biomedical and Health Sciences (RBHS)</i>	2020
Biostatistics Epidemiology Summer Training (BEST) Diversity Program, Co-Mentor <i>Columbia University Mailman School of Public Health</i>	2019

**SPONSORSHIP OF CANDIDATES FOR POSTGRADUATE DEGREE:**

**Doctoral Students**

---

Naomi Cruz (PhD candidate), Dissertation Committee Chair <i>Department of Health Behavior, Society and Policy, Rutgers School of Public Health</i>	2022 – present
Molly Nowels (PhD candidate), Dissertation Committee Member <i>Department of Health Behavior, Society and Policy, Rutgers School of Public Health</i>	2022 – present
Allison Stitt (DrPH candidate), Dissertation Committee Chair <i>Department of Health Behavior, Society and Policy, Rutgers School of Public Health</i>	2023 – present
Allison Perry (PhD student), External Dissertation Committee Member <i>Department of Population Health, Division of Epidemiology, NYU School of Medicine</i>	2023 – present

**Master of Public Health (MPH) Students**

---

Capstone Advisor <i>Department of Health Behavior, Society and Policy, Rutgers School of Public Health</i>	
<input type="checkbox"/> Markin Samad	expected 2024
<input type="checkbox"/> Hemal Patel	expected 2024
<input type="checkbox"/> Alejandra Murillo	expected 2024
<input type="checkbox"/> Ariel Lonoff	expected 2024
<input type="checkbox"/> Sofia Bonsignore	expected 2023
<input type="checkbox"/> Emily Thamhoe	expected 2023
<input type="checkbox"/> Peter Fam	expected 2023
<input type="checkbox"/> Connor Griffin	2023
<input type="checkbox"/> Ethan Pardun	2022

**TEACHING RESPONSIBILITIES:**

**Lectures or Course Directorships**

---

Rutgers School of Public Health, Department of Health Behavior, Society and Policy Mental Health Services and Systems (3 credit hours), Instructor	2023 – present
Health Systems and Policy (3 credit hours), Instructor	2022 – 2023
Rutgers School of Public Health, Department of Biostatistics and Epidemiology Intermediate Pharmacoepidemiology, Guest Lecturer	2022 – 2023
Analysis of Real-World Pharmacoepidemiological Data, Guest Lecturer	2022
Doctoral Colloquium, Guest Lecturer	2022
Rutgers Robert Wood Johnson Medical School, Department of Psychiatry General Psychiatry Residency Program, Guest Lecturer	2022

Columbia University Mailman School of Public Health Substance Abuse Epidemiology Training Program Seminar, Guest Lecturer	2023
<b>Johns Hopkins Bloomberg School of Public Health</b>	2013 – 2016
<i>Teaching Assistant</i>	
The Research and Proposal Writing Process II (2 credit hours)	2016
Research Ethics and Integrity: U.S. and International Issues (3 credit hours)	2015 – 2016
Introduction to Bioethics in Public Health Practice and Research (1 credit hour)	2013 – 2016
The Research and Proposal Writing Process I (2 credit hours)	2015
Assessing Health Status and Patient Reported Outcomes (3 credit hours)	2015
Urban Policy (3 credit hours)	2015
Ethical Issues in Health Policy: Public Health and Health Care (3 credit hours)	2014

#### GRANT SUPPORT:

##### **Principal Investigator**

---

NIH/NIDA Career Development Award (K01 DA049950)	07/2020 – 06/2025
<i>Multi-Level Associations Between Opioid Use and Overdose: Individual, Clinical, and Population-Based Risk Factors for Fatality</i>	\$980,530
NIH/NIDA Loan Repayment Award (L30 DA046889)	07/2018 – 06/2023
<i>Trajectories of Prescription Opioid Use for Chronic Pain and Risk of Adverse Opioid-Related Outcomes</i>	07/2021 – 06/2023
<i>The Clinical Epidemiology of Prescription Opioid Use and Outcomes Among Chronic Pain Patients</i>	07/2020 – 06/2021
<i>The Clinical Epidemiology of Opioid Use Disorder, Overdose, and Medication-Assisted Treatment</i>	07/2018 – 06/2020

##### **Co-Investigator**

---

NIH/NIDA R01 DA059042 (PI: Williams)	07/2023 – 06/2028
<i>The OUD Cascade of Care and Critical Outcomes: Longitudinal Linkage with Opioid Use</i>	\$989,408
NIH/NIDA R01 DA047347-S1 (PI: Crystal)	06/2021 – 01/2024
<i>Fatal and Non-Fatal Opioid Overdose Risk Following Prison Release: Associations with Individual Risk Factors, In-Prison Medications for Opioid Use Disorder, and Peer Navigation</i>	\$311,756
NIH/NIDA R01 DA057568 (PI: Crystal)	09/2022 – 08/2027
<i>Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with Disability</i>	\$2,499,995

#### PUBLICATIONS:

##### **Refereed Original Article in Journal**

- 
1. **Samples H**, Levy NS, Bruzelius E, Segura LE, Mauro PM, Boustead AE, Mauro C, Martins SS. Association between legal access to medical cannabis and frequency of non-medical prescription opioid use among US adults. *Int J Ment Health Addict*. (In press)
  2. Hoffman K, Milazzo F, Williams N, **Samples H**, Olfson M, Diaz I, Doan L, Cerdá M, Crystal S, Rudolph K. Independent and joint contributions of physical disability and chronic pain to incident opioid use disorder and opioid overdose among Medicaid patients. *Psychol Med*. (In press)
  3. Miles J, Treitler P, Hermida R, Nyaku AN, Simon K, Gupta S, Crystal S, **Samples H**. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries. *Drug Alcohol Depend*. 2023; 110963.
  4. Miles J, Treitler P, Lloyd J, **Samples H**, Mahone A, Hermida R, Gupta S, Duncan A, Baaklini V, Simon K, Crystal S. Racial and ethnic disparities in buprenorphine receipt among Medicare Beneficiaries, 2015-19. *Health Aff*. 2023;42(10):1432-1438.

- 
5. **Samples H**, Nowels M, Williams AR, Olfson M, Crystal S. Buprenorphine after non-fatal opioid overdose: Reduced mortality risk in Medicare disability beneficiaries. *Am J Prev Med.* 2023;65(1):19-29. PMID: PMC10293066.
  6. Williams AR, Mauro CM, Feng T, Wilson A, Cruz A, Olfson M, Crystal S, **Samples H**, Chiodo L. Performance measurement for opioid use disorder medication treatment and care retention. *Am J Psychiatry.* 2022;180(6):454-457. PMID: PMC10130230.
  7. Treitler P, **Samples H**, Hermida R, Crystal S. Association of a state prescribing limits policy with opioid prescribing and long-term use: an interrupted time series analysis. *J Gen Int Med.* 2023;38(8):1862-1870. PMID: PMC10271990.
  8. Treitler P, Nowels M, **Samples H**, Crystal S. Buprenorphine utilization and prescribing among New Jersey Medicaid beneficiaries after adoption of initiatives designed to improve treatment access. *JAMA Netw Open.* 2023;6(5):e2312030. PMID: PMC10163388.
  9. Bruzelius E, Cerdá M, Davis CS, Jent V, Wheeler-Martin K, Mauro CM, Crystal S, Keyes KM, **Samples H**, Hasin DS, Martins SS. Naloxone expansion is not associated with increases in adolescent heroin use and injection drug use: Evidence from 44 US states. *Int J Drug Policy.* 2023;114:103980.
  10. Hamilton LK, Wheeler-Martin K, Davis CS, Martins SS, **Samples H**, Cerdá M. A modified Delphi process to identify experts' perceptions of the most beneficial and harmful laws to reduce opioid-related harm. *Int J Drug Policy.* 2022;108:103809. NIHMSID: NIHMS1840454.
  11. **Samples H**, Williams AR, Crystal S, Olfson M. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes. *J Subst Abuse Treat.* 2022;139:108774. PMID: PMC9187597.
  12. Williams AR, Mauro C, Feng T, Wilson A, Wilson A, Cruz A, Olfson M, Crystal S, **Samples H**, Chiodo L. Non-Prescribed Buprenorphine Preceding Treatment Intake and Clinical Outcomes for Opioid Use Disorder. *J Subst Abuse Treat.* 2022;39:108770. PMID: PMC9187606.
  13. **Samples H**. Commentary on Lo-Ciganic et al.: The importance of evidence-based clinical and policy approaches to reduce opioid harms. *Addiction.* 2022;117(7):1998-1999. PMID: PMC9203928.
  14. Nguyen T, Ziedan E, Simon K, Miles J, Crystal S, **Samples H**, Gupta S. Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic. *JAMA Netw Open.* 2022;5(6):e2214765.
  15. Bushnell G, **Samples H**, Gerhard T, Calello DP, Olfson M. Benzodiazepine and stimulant prescriptions before overdose in youth. *Pediatrics.* 2022;149(4):e2021055226. PMID: PMC9097826.
  16. Crystal S, Nowels M, **Samples H**, Olfson M, Williams AR, Treitler P. Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients. *Drug Alcohol Depend.* 2022;232:109269. PMID: PMC8943804.
  17. Mauro P, Gutkind S, Annunziato E, **Samples H**. Utilization of medication for opioid use disorder in a representative sample of U.S. adolescents and adults with need for treatment, 2019. *JAMA Netw Open.* 2022;5(3):e223821. PMID: PMC8943638.
  18. Crystal S, Nowels M, Olfson M, **Samples H**, Williams AR, Treitler P. Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration. *J Subst Abuse Treat.* 2021;131:108456. PMID: PMC8664984.
  19. Martins SS, Bruzelius E, Stingone JA, Wheeler-Martin K, Akbarnejad H, Mauro CM, Marziali M, **Samples H**, Crystal S, Davis CS, Rudolph KE, Keyes KM, Hasin DS, Cerdá M. Prescription opioid laws and opioid-dispensing in U.S. counties: Identifying salient law provisions with machine learning. *Epid.* 2021;32(6):868-876. PMID: PMC8556655.
  20. Mauro P, **Samples H**, Klein K, Martins SS. Discussing drug use with health care providers is associated with perceptions and receipt of drug use treatment in the United States: We need to talk. *Med Care.* 2020;58(7):617-624. PMID: PMC8112806.
  21. **Samples H**, Williams AR, Crystal S, Olfson M. Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid. *Health Aff.* 2020;39(5):747-55. PMID: PMC7531057.
  22. \*Williams AR, **Samples H**, Olfson M, Crystal C. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. *Am J Psychiatry.* 2020;177(2): 117-124. PMID: PMC7002204.  
\*Published with commentary: Connery HS, Weiss RD. Discontinuing Buprenorphine Treatment of Opioid Use Disorder: What Do We (Not) Know? *Am J Psychiatry.* 2020;177(2):104-106.
  23. \***Samples H**, Stuart EA, Saloner B, Barry CL, Mojtabai R. The Role of Screening in Depression Diagnosis and Treatment in a Representative Sample of US Primary Care Visits. *J Gen Int Med.* 2020;35(1):12-20. PMID: PMC6957618.  
\*Published with commentary: Jackson JL, Machen JL. From the Editors' Desk: The Importance of Screening for Depression in Primary Care. *J Gen Intern Med.* 2020;35(1):1-2.

- 
24. \***Samples H**, Stuart EA, Olfson M. Opioid Use and Misuse and Suicidal Behaviors in a Nationally Representative Sample of US Adults. *Am J Epidemiol.* 2019;188(7):1245-1253. PMID: PMC6601526. \*Selected as Editor's Choice
  25. **Samples H**, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. *J Subst Abuse Treat.* 2018;95:9-17. PMID: PMC6354252.
  26. \***Samples H**, Bandara SN, Olfson M, Saloner B. Tobacco Screening and Counseling in the U.S.: Smokers With Mental Health and Substance Use Problems. *Am J Prev Med.* 2018;55(4):524-532. PMID: PMC6363105. \*Selected for *Am J Prev Med* Continuing Medical Education Program
  27. Bandara SN, **Samples H**, Crum RM, Saloner B. Is screening and intervention associated with treatment receipt among individuals with alcohol use disorder? Evidence from a national survey. *J Subst Abuse Treat.* 2018;92:85-90. PMID: PMC6423981.
  28. Huskamp HA, **Samples H**, Hadland SE, et al. Mental health spending and intensity of service use among individuals with diagnoses of eating disorders following federal parity. *Psychiatr Serv.* 2018;69(2):217-223. PMID: PMC5794569.
  29. McGinty EE, **Samples H**, Bandara SN, Saloner B, Bachhuber MA, Barry CL. The Emerging Public Discourse on State Legalization of Marijuana for Recreational Use in the US: Analysis of News Media Coverage, 2010-2014. *Prev Med.* 2016;90:114-120.
  30. \***Samples H**, Mojtabai R. Antidepressant Self-Discontinuation: Results From the Collaborative Psychiatric Epidemiology Surveys. *Psychiatr Serv.* 2015;66(5):455-462. \*Published with commentary: Olfson M. Bringing antidepressant self-discontinuation into view. *Psychiatr Serv.* 2015;66(5):449.
  31. Broshek DK, **Samples H**, Beard J, Goodkin H. Current Practices of the Child Neurologist in Managing Sports Concussion. *J Child Neurol.* 2014;29(1):17-22.
  32. **Samples H**, Mojtabai R. Antidepressant Use in the European Union: Perceived Indications and Patterns. *Psychiatr Serv.* 2013;64(3):208.
  33. Bailey CM, **Samples H**, Broshek DK, Freeman JR, Barth JT. The relationship between psychological distress and baseline sports-related concussion testing. *Clin J Sport Med.* 2010;20(4):272-277.

### Books, Monographs, and Chapters

---

1. Hasin D, **Samples H**. Marijuana Use in the U.S.: Trends, Consequences, Changing Laws. In: Boulton ML, Wallace R (Eds.), *Maxcy-Rosenau-Last Public Health & Preventive Medicine, 16th Edition*. New York: McGraw-Hill; 2022.

### Other Articles

---

1. **Samples H**. Commentary on Lo-Ciganic et al.: The importance of evidence-based clinical and policy approaches to reduce opioid harms. *Addiction.* 2022;117(7):1998-1999. PMID: PMC9203928.
2. Chen S, Barth AT, Barth JT, Bennett BC, Brandt-Pearce M, Broshek DK, Freeman JR, **Samples HL**, Lach J. Aiding diagnosis of normal pressure hydrocephalus with enhanced gait feature separability. In: *Proceedings on the Conference of Wireless Health*. San Diego, CA. Oct 2012. Article 3.

### Abstracts

---

1. **Samples H**, Williams AR, Olfson M, Crystal S. Patterns of psychosocial and behavioral therapy received in conjunction with buprenorphine treatment [Abstract A6]. In: *Addict Sci Clin Pract.* 2020;15(Suppl 2):1-43.
2. Sanders JF, **Samples HL**, Bailey CM, Broshek, DK, Freeman JR, Barth JT. The Effects of Attention Deficit Hyperactivity Disorder and Learning Disability on Baseline Neurocognitive Evaluation in Collegiate Athletes [Abstract 89S]. In: *Clin Neuropsychol.* 2010;24(4):557-645.
3. Bailey CM, **Samples HL**, Broshek DK, Barth JT, Freeman JR. The Influence of Psychological Symptoms on Baseline Concussion Testing [Abstract C39]. In: *Arch Clin Neuropsych.* 2009;24(5):431-540.

## PRESENTATIONS:

### Scientific

---

1. **Samples H**, Nowels M, Williams AR, Olfson M, Crystal S. Buprenorphine after non-fatal opioid overdose: Reduced mortality risk in Medicare disability beneficiaries. Oct 2023. Podium presentation, Addiction Health Services Research Conference: New York, NY.
2. **Samples H**, Ryali R, Martins SS, Cerda M, Hasin D, Crystal S, Olfson M. Completeness and Quality of Managed Care Data for Research Using National Medicaid Files: A Validation Study. Jun 2023. Podium presentation, Annual Research Meeting of Academy Health: Seattle, WA.
3. **Samples H**, Williams AR, Olfson M, Crystal S. Prescription opioid tapering patterns prior to discontinuation of long-term, high-dosage treatment episodes among adult Medicaid enrollees. Jun 2023. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: Denver, CO.
4. Fink DS, **Samples H**, Saxon A, Malte C, Wall MM, Hasin DS. State Cannabis Legalization and Changes in Cannabis Use as Determined by Biologic Testing in Emergency Department Patients in the U.S. Veterans Health Administration, 2008 to 2019. Jun 2023. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: Denver, CO.
5. Fink DS, **Samples H**, Saxon A, Malte C, Wall MM, Hasin DS. State Cannabis Legalization and Changes in Cannabis Use as Determined by Biologic Testing in Emergency Department Patients in the U.S. Veterans Health Administration, 2008 to 2019. Jun 2023. Podium presentation, Annual Meeting of the Society for Epidemiologic Research: Portland, OR.
6. Nowels M, Duberstein PR, Crystal S, Treitler P, Olfson M, **Samples H**. Predictors of death by suicide among Medicare disability enrollees surviving medically-treated opioid overdoses. Apr 2023. Podium presentation, Annual Suicide Research Symposium.
7. Cruz NA, Kleiman EM, **Samples H**. Exploring the Relationship between Eating Disorders, Suicidality, Adversity, and COVID-19 among U.S. College Students. Apr 2023. Poster presentation, Annual Suicide Research Symposium.
8. Cruz NA, **Samples H**. Risk Factors for Suicide Attempts in a Nationally Representative Sample of Adolescents Aged 12-17. Mar 2023. Poster presentation, Annual Meeting of the American Psychopathological Association: New York, NY.
9. \*Cruz NA, **Samples H**. Characteristics Associated with Suicidal Ideation and Suicide Attempts in a Nationally Representative Sample of Adolescents Aged 12-17. Mar 2023. Poster presentation, Annual Meeting of the American Psychopathological Association: New York, NY.  
\*Scholarship award
10. Treitler P, Nowels M, **Samples H**, Crystal S. Evaluating the relationship of state Medicaid initiatives with patient- and provider-level changes in buprenorphine treatment for opioid use disorder. Jan 2023. Poster presentation, International Conference on Health Policy Statistics: Scottsdale, AZ.
11. Hamilton L, Wheeler-Martin K, Davis CS, Martins SS, **Samples H**, Cerdá M. Expert Consensus on the Most Beneficial and Harmful Opioid Laws: A Policy Delphi Process. (Jun 2022). Poster presentation, Annual Meeting of the Society for Epidemiologic Research.
12. **Samples H**, Williams AR, Crystal S, Olfson M. Characteristics of new long-term prescription opioid treatment episodes among Medicaid enrollees with chronic non-cancer pain. (Oct 2021). Poster presentation, Addiction Health Services Research Conference.
13. Nowels M, **Samples H**, Treitler P, Olfson M, Crystal S. Overdose Mortality Following a Medically-Treated Opioid Overdose in Medicare Disability Enrollees, 2008-2016. (Oct 2021). Poster presentation, Addiction Health Services Research Conference.
14. Williams AR, Mauro C, Feng T, Wilson A, Cruz A, Olfson M, Crystal S, **Samples H**, Chiodo L. Non-Prescribed Buprenorphine and Clinical Outcomes for Opioid Use Disorder. (Oct 2021). Poster presentation, Addiction Health Services Research Conference.
15. Nguyen T, Gupta S, Ziedan E, Miles J, **Samples H**, Crystal S, Simon K. Racial/ethnic disparities in access to MOUD during the Covid-19 Pandemic. (Oct 2021). Poster presentation, Addiction Health Services Research Conference.
16. Miles J, Treitler P, **Samples H**, Hermida R, Nyaku A, Simon K, Gupta S, Ziedan E, Crystal S. Racial/ethnic disparities in buprenorphine initiation among Medicare disability beneficiaries (Oct 2021). Poster presentation, Addiction Health Services Research Conference.
17. Mauro P, Gutkind S, **Samples H**. Epidemiology of Medication for Opioid Use Disorder Utilization in the United States in 2019. (Jun 2021). Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence.

- 
18. Brown Q, **Samples H**, Montgomery L, Hasin D, Campbell C, Crystal S. Cannabis Use and Perceived Risk among Pregnant Women in the US by Trimester. (Jun 2021). Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence.
  19. Martins SS, Bruzelius E, Stingone JA, Wheeler-Martin K, Akbarnejad H, Mauro CM, Marziali M, **Samples H**, Crystal S, Davis CS, Rudolph KE, Keyes KM, Hasin DS, Cerdá M. (Dec 2020). Prescription opioid laws and opioid-related harm: Identifying salient opioid policy features with machine learning. Poster presentation, Annual Meeting of the Society for Epidemiologic Research.
  20. \***Samples H**, Williams AR, Crystal S, Olfson M. Patterns of Psychosocial and Behavioral Therapy Received in Conjunction with Buprenorphine Treatment. Oct 2020. Podium and poster presentations, Addiction Health Services Research Conference.  
\*Early Career Investigator Award
  21. Crystal S, Nowels M, Hermida R, Williams AR, Samples H, Olfson M. Medically Treated Opioid Overdoses in NJ Medicaid Beneficiaries 2014-2017: Rapid Growth with Complex Comorbidity. Jun 2020. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence.
  22. **Samples H**, Williams AR, Crystal S, Olfson M. Reduced Adverse Health Care Outcomes with Continuous Buprenorphine Treatment Beyond 6 to 9 Months. Oct 2019. Podium presentation, Addiction Health Services Research Conference: Park City, UT.
  23. Williams AR, **Samples H**, Crystal S, Olfson M. Long-term buprenorphine treatment for OUD and adverse events following discontinuation among Medicaid beneficiaries. Oct 2019. Podium presentation, Addiction Health Services Research Conference: Park City, UT.
  24. Crystal S, Nowels M, Hermida R, Williams AR, **Samples H**, Olfson M. Medically Treated Opioid Overdoses among Medicaid Beneficiaries: Changing Profiles and Evolving Clinical Challenges. Oct 2019. Poster presentation, Addiction Health Services Research Conference: Park City, UT.
  25. **Samples H**, Williams AR, Crystal S, Olfson M. Reduced adverse health care utilization outcomes among Medicaid enrollees with buprenorphine treatment continuity vs. discontinuation after 6-9 months. Jun 2019. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: San Antonio, TX.
  26. **Samples H**, Williams AR, Olfson M, Crystal S. Risk Factors for Premature Discontinuation of Buprenorphine Treatment for Opioid Use Disorder among Medicaid Enrollees. Jun 2018. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: San Diego, CA.
  27. Mauro PM, **Samples H**, Klein KS, Martins SS. Are discussions about substance use in health care settings associated with substance use disorder treatment use and perception of treatment need? Jun 2018. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: San Diego, CA.
  28. **Samples H**, Williams AR, Olfson M, Crystal S. Predictors of Buprenorphine Treatment Discontinuation in a Medicaid Population with Opioid Use Disorder. May 2018. Poster presentation, The Opioid Tsunami: Prevention, Partnerships in Opioid Management, and Current Issues; Annual Isabel Maitland Stewart Conference on Research in Nursing: New York, NY.
  29. **Samples H**, Williams AR, Olfson M, Crystal S. Duration of Medication-Assisted Treatment for Opioid Use Disorders Among Adults with Medicaid Insurance. Mar 2018. Podium presentation, NIDA/NIMH T32 meeting at the Annual Meeting of the American Psychopathological Association, New York, NY.
  30. Broshek DK, **Samples HL**, Beard JB, Goodkin HP. Current Practices of the Pediatric Neurologist in the Management of Sports Concussion. Oct 2011. Poster presentation, Annual Meeting of the Child Neurology Society: Savannah, GA.
  31. Sanders JF, **Samples HL**, Bailey CM, Cuttita K, Broshek DK, Freeman JR, Barth JT. Differences in Preseason Baseline Functioning & Cognitive Efficiency of Athletes with ADHD/LD and Controls. May 2010. Poster presentation, University of Virginia Research and Scholars Day: Charlottesville, VA.
  32. Sanders JF, **Samples HL**, Bailey CM, Broshek, DK, Freeman JR, Barth JT. The Effects of Attention Deficit Hyperactivity Disorder and Learning Disability on Baseline Neurocognitive Evaluation in Collegiate Athletes. May 2010. Poster presentation, Annual Meeting of the American Academy of Clinical Neuropsychology: Chicago, IL.
  33. Bailey CM, **Samples HL**, Broshek DK, Barth JT, Freeman JR. The Influence of Psychological Symptoms on Baseline Concussion Testing. Nov 2009. Poster presentation, Annual Conference of the National Academy of Neuropsychology: New Orleans, LA.

---

## Professional

1. National trends in suicidal ideation and attempts. May 2023. Suicide Risk Reduction Project, The Pew



- 
- Charitable Trusts: Washington, DC.
2. Reducing disparities in suicide-related treatment and outcomes in an evolving risk environment. Feb 2023. Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV (CHERISH), Weill Cornell Medicine: New York, NY.
  3. Research to reduce the burden of opioid-related morbidity and mortality. Dec 2022. Center for Pharmacoepidemiology and Treatment Science Research Rounds, Rutgers University: New Brunswick, NJ.
  4. Identifying targets to address disparities in suicide prevention and mortality in an evolving risk environment. Dec 2022. Suicide Prevention and Research Center (SPARC), Rutgers University: New Brunswick, NJ.
  5. Completeness and quality of managed care data in national Medicaid claims: A validation study. Nov 2022. Medicaid Data Learning Network, Academy Health: Washington, DC.
  6. Research to inform evidence-based approaches to address the opioid epidemic. Sep 2022. Rutgers Addiction Research Center (RARC) Retreat: Piscataway, NJ.
  7. Opioid use disorder treatment and mortality risk after non-fatal opioid overdose. Mar 2022. Substance Abuse Epidemiology Training Program Faculty-Fellow Seminar, Columbia University Mailman School of Public Health: New York, NY.
  8. Trajectories of Long-term Prescription Opioid Use and Adverse Opioid-Related Outcomes. Oct 2021. Division on Comparative Effectiveness and Outcomes Research Seminar, Weill Cornell Medicine Population Health Sciences: New York, NY.
  9. Prescription opioid treatment and risk of adverse opioid-related outcomes among individuals with chronic pain. Jul 2021. Special Populations Core Webinar Series, NJ Alliance for Clinical and Translational Science.
  10. Patterns of opioid-related prescription drug use and the association with clinical outcomes. Jun 2021. Center for Pharmacoepidemiology and Treatment Science (PETS) Seminar, Rutgers Institute for Health, Health Care Policy and Aging Research: New Brunswick, NJ.
  11. Medicaid Policy Changes in Response to COVID-19. Jun 2020. Opioid Workgroup, Institute for Health, Health Care Policy and Aging Research, Rutgers University: New Brunswick, NJ.
  12. Buprenorphine Treatment Duration: All-cause and Opioid-specific Clinical Benefits of Continuous Care. May 2020. Division on Substance Use Disorders, New York State Psychiatric Institute: New York, NY.
  13. Proposed Study of Changes in Opioid Use Disorder Treatment Patterns and Outcomes Associated with the 2019 Novel Coronavirus. Apr 2020. Substance Abuse Epidemiology Training Program Faculty-Fellow Seminar, Columbia University Mailman School of Public Health: New York, NY.
  14. A Translational Approach to Understanding the Opioid Epidemic and Identifying Targets for Intervention. Dec 2019. Institute for Health, Health Care Policy and Aging Research, Rutgers University: New Brunswick, NJ.
  15. A Proposal to Study Multi-level Risk Factors for Overdose among Medicaid Patients with Chronic Pain and Opioid Use. Oct 2019. Substance Abuse Epidemiology Training Program Faculty-Fellow Seminar, Columbia University Mailman School of Public Health: New York, NY.
  16. A Translational Approach to Understanding the Opioid Epidemic and Identifying Targets for Intervention. May 2019. Population Health Research Seminar, New York University School of Medicine: New York, NY.
  17. Opioid Addiction Treatment Duration and Outcomes in Medicaid Populations. Dec 2018. Consortium on Applying Evidence to Improve Care and Outcomes for Individuals with Co-occurring Severe Mental Illness and Substance Use Disorders, Rutgers University Institute for Health, Health Care Policy, and Aging Research: New Brunswick, NJ.
  18. Opioid Addiction Treatment Continuity and Health Care Utilization in Medicaid. Nov 2018. Substance Abuse Epidemiology Training Program Faculty-Fellow Seminar, Columbia University Mailman School of Public Health: New York, NY.
  19. Determinants of Retention in Buprenorphine Treatment Among Medicaid Patients with Opioid Use Disorders. Feb 2018. Substance Abuse Epidemiology Training Program Faculty-Fellow Seminar, Columbia University Mailman School of Public Health: New York, NY.
  20. An Investigation of Capacity to Consent to Research. Aug 2014. Presidential Commission for the Study of Bioethical Issues, DHHS: Washington, D.C.